US Patent 10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
Patent 10266595 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
